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Analysis of human biological material (HBM) is quite lucrative.1 De-
veloping countries’ ethical and regulatory frameworks are influenced 
by debates between Europe and the USA, and their regulations. 
Hence, traditional cultural values placed on HBM by communities 
in developing countries might not be considered. The frameworks 
of selected developed countries2 (Australia, Canada, the UK and 
USA), selected developing countries in Africa2 (Kenya, Malawi, Ni-
geria Tanzania, Uganda and Zimbabwe) and the BRICS countries2 
(Brazil, Russia, India, China and South Africa) were reviewed and 
compared for robustness of ethical protection of HBM in research.
Key organisations, laws, regulations 
and guidelines
All research on humans in Australia and Canada is guided respec-
tively by The National Statement3 and The Australian Code,4 and 
also the Interagency Advisory Panel on Research (PRE) Tri-Coun-
cil Policy Statement (TCPS2).5 In the UK, the Human Tissue Act 
of 2004 (UKHTAct)6 applies in full in England, Wales and Northern 
Ireland, but not in full in Scotland. The Act established the Human 
Tissue Authority (HTA)7 as the overseeing body corporate which 
deals with issues about the use of HBM for research. In the USA, 
the Department of Health and Human Science’s (DHHS) Code of 
Federal Regulations (CFR) (title 45 part 46) [54CFR46]8 (also re-
ferred to as the Common Rule) governs human subject research. 
Oversight of these federal regulations is delegated to the Office of 
Human Protection Research (OHRP) which monitors compliance.
In the selected developing countries in Africa (Kenya,9 Malawi,10,11 
Nigeria,12 Tanzania,13 Uganda14 and Zimbabwe),15 their respective 
national research ethics committees or councils are responsible 
for developing regulations, guidelines and co-ordinating all human 
subject research.
In the RSA, the national ethics regulations are governed by the 
National Health Act (NHA) [Act No 61 of 2003].16 Legal aspects 
of using HBMs are governed by Chapter 8 of the Act. The De-
partment of Health (DoH) has promulgated complementary 
guidelines.17,18 The Health Professions Council of South Africa 
(HPCSA),19,20 and the Medical Research Council of South Africa 
(SAMRC),21,22 have independently published research ethics 
guidelines. The South African Intellectual Property Rights from 
Publicly Financed Research and Development Act (IPR Act)23 
regulates intellectual property rights, patents and benefits that 
may be applicable to HBMs.
In Brazil, the Comissao Nacional de Ethica em Pesquisa (Na-
tional Commission for Research Ethics) (CONEP) is respon-
sible for assessing ethical issues arising from all research 
involving human participants. Resolution 196 (the standard 
guidelines for participant protections) is used. HBM research is 
regulated in complementary resolutions that include the need 
for a memorandum of co-operation for foreign research, special 
protections for indigenous peoples, and information on storage 
or use of HBM.24-27
The Indian Council of Medical Research (ICMR) formulates, co-
ordinates and promotes biomedical research in India28 and col-
laboration between India and other foreign agencies through the 
Indo-Foreign Cell (IFC).
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Definitions of HBM
In the UK’s UKHT Act,6 ‘tissue’ refers to ‘any, and all, constituent 
part(s) of the human body formed by cells’ and is divided into ‘rel-
evant and bodily material’. When a sample contains even a single 
human cell, it is classified as ‘relevant material.’ The USA’s policy 
and guideline documents of the OHRP and the National Bioeth-
ics Advisory Committee (NBAC) use interchangeably ‘biological 
materials, human biological specimens, human tissue materials 
and biological specimens’ without providing any definitions,29-31 
although the National Cancer Institute of the National Institute of 
Health (NIH) provides comprehensive definitions for ‘biospeci-
mens’ and ‘specimens’.32 TCPS25 in Canada and The Australian 
Code4 refer to ‘biological materials’, the latter without providing a 
definition.
The Ugandan national guideline is the only one in Africa (exclud-
ing BRICS) that refers to HBM and includes ‘microorganisms’ in its 
definition.14 ‘Human tissue’ is defined in the Kenyan9 and Tanzani-
an13 national guidelines. The Malawian guidelines refer to ‘genetic 
resources’ in the context of ‘agricultural/forestry/fisheries/parks 
and wildlife resources’ and not HBM.10,11 The Nigerian national 
guidelines refer to ‘samples and biological materials’ that include 
‘herbs and plants’ without defining what constitutes ‘samples’ or 
‘biological materials.’12 The Zimbabwean national guidelines pro-
vide no definitions15 except guidelines for the collection of blood 
samples.33
Of the BRICS countries, only India provides a comprehensive 
definition of HBMs.28 The RSA national ethics guidelines defines 
the constituents of ‘human tissue’,17 while the National Health Act 
(NHA) defines ‘biological materials’34 and ‘tissues’,35 where ‘tis-
sues’ is used collectively to indicate cells and tissues, including 
stem cells. In Brazil, Resolution 196/96 refers to ‘scientific mate-
rial, tissue, organs, other parts of the human body and biological 
materials’ without providing a definition of what constitutes these 
materials.24
Indentifiability of HBM
The various frameworks have no consistency in the level of iden-
tifiably used for HBM. Europe36 and Canada5 use 5 levels of iden-
tifiablity. The Indian28 and American37 frameworks distinguish be-
tween samples that are stored in repositories and samples that are 
collected for research. The RSA17 and Australia3 define 3 catego-
ries, while Kenya9 and Tanzania13 guidelines refer to 2 categories. 
None of the frameworks of the developing countries in Africa pro-
vides for nor defines the levels of identifiability for HBM.
Informed consent (IC)
Developed countries favour either broad consent or multilayered 
consent3,5,6,7,37,38 for the use of their HBM. Developing countries in 
Africa9-15 and the BRICS17,22,27,28 favour specific and multilayered 
consent. Broad consent allows investigators and other secondary 
users access to HBM in current and all unspecified future research 
anytime and anywhere. Multilayered consent provides research 
participants with several options, while specific consent allows use 
of HBM only in current research, and research participants must 
obtain consent for new use of their HBM that is outside the scope 
of the original consent.
Material transfer agreements (MTAs) and export 
permits (EPs)
Material transfer agreements (MTAs) are legally binding contracts 
that govern the transfer of HBM between collaborating research-
ers and institutions. The frameworks of developed countries, de-
veloping countries in Africa and BRICS countries require MTAs 
and permits for the import and export of HBM. In the RSA, the 
NHA16 is silent on the requirement of an MTA or an intellectual 
property right (IPR) for the transfer and use of HBM in international 
collaborative research. However, the IPR Act (Act No 51 of 2008) 
may apply to HBM.23 Of the national guidelines, only the HPCSA19 
makes an MTA mandatory before tissues leave the country.
Discussion
The absence of a globally acceptable uniform definition of HBM 
causes confusion, ambiguities and difficulties. The extent to which 
the identity of HBM can be linked with the identity of its source is 
important in assessing the potential risks and benefits to the pro-
vider of the material. The use of many terms to describe different 
levels of identifiability and their differing interpretations has been 
problematic in defining confidentiality.39 As a step towards harmo-
nisation, the International Conference on Harmonisation of Tech-
nical Requirements (ICH)40 adopted 4 levels of identifiability, i.e. 
identified, coded, anonymised and anonymous. When research is 
conducted with HBM that is not identifiable and cannot be linked 
through a system of codes, the OHRP’s Common Rule (45CFR 
46)8 considers such research as ‘non human.’ The Common Rule 
allows researchers unlimited use of leftover clinical specimens for 
any type of unspecified future research without IC or REC approv-
al. Some individuals and communities object to certain uses of 
their HBM to the extent of instigating lawsuits.41 In the wake of the 
Tuskegee Syphilis and Guatemala scandals and the Havasupai 
Indian Tribe Case, President Obama issued an executive order 
to re-examine the Common Rule and all federal regulations, to 
consider consistency of regulations across the federal government 
and to extend federal oversight over all research in the USA.42
Defining IC requirements for collecting, storing and using HBM 
for research remains a controversial international issue.43 While 
most developed countries support broad consent, studies suggest 
that broad consent has not been convincingly embraced by all re-
search communities,44-49 and they question the appropriateness of 
applying the IC formats of highly industrialised, individualist coun-
tries such as the USA and UK to manage HBM in cross-cultural 
settings and communitarian societies in developing countries, in-
cluding those in Africa.50
Permits to export and import HMB are a legal requirement 
in most jurisdictions. In the UK, the HTA recommends that, 
whenever possible, the import and export of tissues be con-
ducted via the HTA licensing regime under the supervision of a 
‘designated individual (DI)’ named on the license.7 In the RSA, 
anecdotal evidence suggests that HBM and data might be reg-
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ularly leaving the country, undocumented and unaccounted for 
at a national level51 without explicit consent, and the fate of 
the HBM is unknown.52 The NHA makes it a criminal offence 
punishable by a fine or imprisonment to export HBM without 
an export permit.53
It has been recommended that benefits derived from using HBMs 
are best addressed through MTAs and IPR agreements.54 Devel-
oping countries in Africa and BRICS regions require an MTA when 
using HBM in collaborative research with developed countries. 
The latter require MTAs for collaborations intra-nationally and 
between developed countries and take the position ‘that MTAs 
should not contain legally binding benefit sharing arrangements 
and restrictions on IP rights and that reference should be made 
only to guidelines’,55 perhaps because guideline documents are 
not legally binding.
In landmark cases in the UK and USA,41 the courts ruled, with 
reference to their national case laws, state health and safety laws, 
that research participants who ‘donate’ their HBM for research, 
make an irrevocable gift. The courts implied that research partici-
pants waived their rights to their HBM in accordance with properly 
obtained IC. These rulings were based solely on ownership and 
property rights. The Nuffield Council on Bioethics (NCB) proposed 
that HBM removed from patients during their treatment should be 
considered as ‘abandoned’,38 effectively denying rights to tissue 
providers over their removed tissues. Under such circumstances, 
benefits accrue only to the institutions in possession of HBM. In 
the Havasupai case, the US Appeal Court ruled that researchers 
from the University of Arizona return HBM to the Havasupai native 
Americans.48 Thus, the court respected the traditional customs of 
the Havasupai native Americans and recognised their right of cus-
tody and ownership of their HBM. Ownership of HBM has not been 
tested in South African Courts.
The lack of uniformity extends to the duration of storage of HBM 
obtained for research. Several policy statements recommend 
that HBM is stored for limited periods and not beyond the end 
date of a specific research project56 unless the original IC did 
not prohibit ‘unlimited time’ for the storage of HBM. The Royal 
College of Pathologists (UK) specify storage periods from 24 
hours up to ‘at least 30 years’, depending on donor consent and 
on the type of HBM.57 The WHO recommends that genetic ma-
terial (DNA) should be stored for as long as it can be of benefit 
to living or future relatives.58 The RSA national ethics guidelines 
place the responsibility on institutions to develop policies regu-
lating the conduct of research using HBM.16 In Brazil, Resolu-
tion 347 in the guidelines on biobanks, authorises storage of 
HBM for 5 years.27
Conclusion
Differing definitions of what constitutes HBMs terms to describe 
identifiability and confidentiality, models of IC, and ambiguous regu-
latory language, are confusing and make comparisons of laws, reg-
ulations and guidelines of the different countries difficult and highly 
complex. There is also no general consensus as to how long HBM 
can and should be stored for research. These are serious impedi-
ments to ethical conduct of biomedical research involving HBM, and 
there is an urgent need to harmonise laws and regulations globally. 
This must reflect and embrace the interests and opinions of commu-
nities who altruistically provide HBM, as legitimate stakeholders, to 
advance medical knowledge and improve healthcare without com-
promising or hindering collaborative research. There must also be a 
paradigm shift from viewing HBM not only as a proprietary good, but 
also as a national resource for the common good.
With the troubled history of vulnerable populations in developing coun-
tries being exploited for their HBM, local national guidelines and laws 
require urgent amendment to include the need for MTAs when HBM 
is used in collaborative research. This could go a long way to end op-
portunities for the proliferation of undesirable and unethical practices.
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